Business Summary
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Number of employees: 11,067
Sales per Business
JPY in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
93.2
%
| 684,434 | 91.9 % | 691,458 | 93.2 % | +1.03% |
Other
6.8
%
| 59,969 | 8.1 % | 50,293 | 6.8 % | -16.14% |
Sales per region
JPY in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Americas
34.2
%
| 239,293 | 32.1 % | 253,756 | 34.2 % | +6.04% |
Japan
30.5
%
| 250,327 | 33.6 % | 226,445 | 30.5 % | -9.54% |
China
14.7
%
| 108,562 | 14.6 % | 109,283 | 14.7 % | +0.66% |
Europe
12.2
%
| 86,026 | 11.6 % | 90,528 | 12.2 % | +5.23% |
Other
8.3
%
| 60,195 | 8.1 % | 61,739 | 8.3 % | +2.56% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/75/01 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Keisuke Naito
COO | Chief Operating Officer | 35 | 01/13/01 |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Lynn Kramer
CTO | Chief Tech/Sci/R&D Officer | 73 | 01/09/01 |
Kenta Takahashi
BRD | Director/Board Member | 64 | 01/83/01 |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01/88/01 |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01/82/01 |
Masatomi Akana
IRC | Investor Relations Contact | 57 | 01/90/01 |
Sayoko Sasaki
IRO | Public Communications Contact | 55 | 01/91/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 01/75/01 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 01/21/01 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
Kenta Takahashi
BRD | Director/Board Member | 64 | 01/83/01 |
Ryota Miura
BRD | Director/Board Member | 50 | 01/21/01 |
Yuko Yasuda
BRD | Director/Board Member | 62 | - |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 01/88/01 |
Yumiko Miwa
BRD | Director/Board Member | 58 | 01/20/01 |
Director/Board Member | 59 | 17/22/17 | |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 01/82/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 296,566,949 | 278,322,831 ( 93.85 %) | 9,531,401 ( 3.214 %) | 93.85 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
EISAI CO., LTD. 3.37% | 9,984,641 | 3.37% | 429,070,477 $ |
MATSUKIYOCOCOKARA & CO. 1.97% | 8,445,000 | 1.97% | 119,195,686 $ |
COGSTATE LIMITED 6.87% | 11,738,243 | 6.87% | 9,680,059 $ |
474,000 | 0.96% | 9,486,333 $ | |
ROIVANT SCIENCES LTD. 0.11% | 874,957 | 0.11% | 9,064,555 $ |
VITAL KSK HOLDINGS, INC. 1.24% | 642,154 | 1.24% | 5,541,128 $ |
349,000 | 0.43% | 3,202,508 $ | |
546,000 | 2.24% | 2,998,490 $ | |
56,608 | 0.14% | 173,990 $ | |
SUZUKEN CO., LTD. 0.00% | 100 | 0.00% | 3,020 $ |
Company contact information
![address Eisai Co., Ltd.(ESALY)](https://cdn.zonebourse.com/static/address/120787943.png)
Group companies
Name | Category and Sector |
---|---|
Eisai Ltd. (United Kingdom)
![]() Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Ltd. is a British company that develops pharmaceutical products. The company is based in Hatfield, UK. The company was founded in 1988. Gary Bryan Hendler has been the CEO of the company since 2008. |
Pharmaceuticals: Major
|
Eisai Pharmaceuticals India Pvt Ltd.
![]() Eisai Pharmaceuticals India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Pharmaceuticals India Pvt Ltd. is an Indian company that manufactures and exports drug substances. The company is based in Visakhapatnam, India. The company was founded in 2007. The CEO is Sanjit Singh Lamba. |
Pharmaceuticals: Major
|
Eisai Manufacturing Ltd.
![]() Eisai Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Manufacturing Ltd. is a pharmaceutical company based in Hatfield, UK. The British company's focus is on developing new medicines for neglected tropical diseases and malaria, improving access to medicines for non-communicable diseases, and promoting sustainability. Eisai Manufacturing is committed to funding the 3rd phase of health innovative technology fund activities. The company's official corporate website provides information on their initiatives and HHC concept. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+56.68% | 809B | |
+39.52% | 624B | |
-7.15% | 351B | |
+7.24% | 289B | |
+13.74% | 240B | |
+13.83% | 220B | |
-0.49% | 219B | |
+8.07% | 166B | |
-2.61% | 157B |